

Ryan K Shields

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9724205/ryan-k-shields-publications-by-year.pdf>

Version: 2023-05-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

5,056
citations

43
h-index

69
g-index

124
ext. papers

6,104
ext. citations

5.3
avg, IF

5.97
L-index

#	Paper	IF	Citations
110	Ceftolozane/tazobactam for refractory <i>P. aeruginosa</i> endocarditis: A case report and pharmacokinetic analysis. <i>Journal of Infection and Chemotherapy</i> , 2022 , 28, 87-90	2.1	1
109	Structural Characterization of the D179N and D179Y Variants of KPC-2 β -Lactamase: β -Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , e0241421	5.6	0
108	Convergent Evolution of Antibiotic Tolerance in Patients with Persistent Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia.. <i>Infection and Immunity</i> , 2022 , e0000122	3.6	
107	Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC β -Lactamase.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , e0212421	5.6	1
106	Isolation and Characterization of Lytic Bacteriophages Targeting Diverse Enterobacter spp. Clinical Isolates. <i>Phage</i> , 2022 , 3, 50-58	1.6	0
105	Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.. <i>Microbial Drug Resistance</i> , 2022 ,	2.8	2
104	Cefiderocol for the Treatment of Infections Due To Metallo-Beta-Lactamase-Producing Pathogens in the CREDIBLE-CR And APEKS-NP Phase 3 Randomized Studies.. <i>Clinical Infectious Diseases</i> , 2022 ,	11.3	1
103	Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000-2017. <i>Clinical Infectious Diseases</i> , 2021 , 73, e4521-e4530	11.3	9
102	Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and <i>Achromobacter xylosoxidans</i> Infections. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1754-e1757	11.3	7
101	Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2021 , 73, 416-426	11.3	18
100	In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant. <i>Antibiotics</i> , 2021 , 10,	4.7	3
99	Molecular epidemiology, natural history and long-term outcomes of multi-drug resistant Enterobacterales colonization and infections among solid organ transplant recipients. <i>Clinical Infectious Diseases</i> , 2021 ,	11.3	1
98	Susceptibility of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.6	10
97	Hydrolytic activity of KPC-producing clinical isolates. <i>Journal of Chemotherapy</i> , 2021 , 1-2	2.2	0
96	Evolution of Cefiderocol Resistance in an NDM-Producing <i>Klebsiella pneumoniae</i> Due to Functional Loss of CirA. <i>Microbiology Spectrum</i> , 2021 , e0177921	8.4	4
95	Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofaa571	0.9	
94	Contemporary Perspective on the Treatment of <i>Acinetobacter baumannii</i> Infections: Insights from the Society of Infectious Diseases Pharmacists. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 2177-2202	6	0

93	Sequence type-258 carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates in which ceftazidime-avibactam resistance emerged are not hypermutators. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020 , 96, 114954	2.8	1
92	Aztreonam Combination Therapy: An Answer to Metallo- β -Lactamase-Producing Gram-Negative Bacteria?. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1099-1101	11.3	18
91	Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. <i>Clinical Infectious Diseases</i> , 2020 , 71, 667-671	11.3	40
90	Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant <i>Klebsiella pneumoniae</i> in a tandem in vitro time-kill/in vivo <i>Galleria mellonella</i> survival model analysis. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105852	13.9	7
89	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3023-3028	4.9	7
88	Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Due to AmpC R2 Loop Deletion. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.6	23
87	Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.6	9
86	Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.6	10
85	Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible spp. at a Tertiary Health Care Center over 2 Decades. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.4	4
84	Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in <i>Enterobacter cloacae</i> Complex Following Exposure to Cefepime. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2713-2716	11.3	23
83	Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Meningitis. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa549	0.9	4
82	High-Level Carbapenem Resistance in OXA-232-Producing <i>Raoultella ornithinolytica</i> Triggered by Ertapenem Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.6	8
81	Evolution of Outbreak-Causing Carbapenem-Resistant <i>Klebsiella pneumoniae</i> ST258 at a Tertiary Care Hospital over 8 Years. <i>MBio</i> , 2019 , 10,	7.6	21
80	Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in <i>Klebsiella pneumoniae</i> ST258. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2203-2208	4.9	1
79	Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of in a Hollow Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.6	6
78	Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 95, 114856	2.8	13
77	Patient-to-Patient Transmission of <i>Klebsiella pneumoniae</i> Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.6	10
76	Amphotericin B Induction with Voriconazole Consolidation as Salvage Therapy for -Associated Echinocandin Resistance in <i>Candida glabrata</i> Septic Arthritis and Osteomyelitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.6	6

75	Effects of KPC Variant and Porin Genotype on the Activity of Meropenem-Vaborbactam against Carbapenem-Resistant. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.6	39
74	Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.6	18
73	Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible <i>Pseudomonas aeruginosa</i> in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019 , 68, 2045-2052	11.3	21
72	Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.6	129
71	Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.6	12
70	Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2018 , 56,	9.4	26
69	1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant <i>K. pneumoniae</i> and <i>P. aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2018 , 5, S419-S420	0.9	13
68	2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S729-S729	0.9	1
67	2421. Tedizolid Is Well-Tolerated Among Patients Receiving Prolonged Treatment Courses. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S724-S724	0.9	78
66	1064. Clinical Outcomes of Daptomycin in Combination With Ceftaroline or Anti-Staphylococcal Penicillins for Patients With Persistent MRSA Bacteremia. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S318-S318	0.9	78
65	1528. A Real-World Perspective on Treatment of CRE UTIs With Oral Agents. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S474-S474	0.9	78
64	2403. Comparison of Daptomycin Combination Therapy With Ceftaroline or Oxacillin Against Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Isolates Causing Persistent Bacteremia. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S717-S718	0.9	78
63	2420. A Real-World Perspective on the Efficacy of Fosfomycin for Treatment of Multidrug-Resistant Pathogens Causing Urinary Tract Infections. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S723-S724	0.9	1
62	247. Sustaining Excellence of Care During a Fluid Shortage: Snapshot of Antibiotic Mitigation Strategies Following Hurricane Maria. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S105-S105	0.9	78
61	357. <i>Aspergillus</i> Isolates Remain Largely Susceptible to Azoles and Other Antifungals at a Large Transplant Program Using Azole Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S140-S140	0.9	78
60	706. Ceftazidime-Avibactam (CZA) and Meropenem (MER) Are Synergistic and Bactericidal Against Genetically Diverse KPC-Producing <i>Klebsiella pneumoniae</i> (Kp). <i>Open Forum Infectious Diseases</i> , 2018 , 5, S254-S254	0.9	78
59	2033. Incorporating T2Candida Testing into Rational Antifungal (AF) Management: A Successful Pilot Study of Diagnostic Stewardship (DS) Directed Toward Specific Intensive Care Unit (ICU) Patients At-Risk for Sepsis due to Invasive Candidiasis (IC). <i>Open Forum Infectious Diseases</i> , 2018 , 5, S592-S593	0.9	78
58	Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.6	17

57	Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx102	0.9	29
56	Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.6	28
55	Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.6	46
54	Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Carbapenemase-Producing : A Case Report and Review of Literature. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx101	0.9	73
53	Therapeutic Drug Monitoring (TDM) of Suspension (SUS), Extended-Release (ER), and Intravenous (IV) Posaconazole (POS) at a Large Transplant Center. <i>Open Forum Infectious Diseases</i> , 2017 , 4, S297-S297	0.9	78
52	Mutations in That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.6	112
51	Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible <i>Klebsiella pneumoniae</i> Isolates with Variant KPC-3 Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.6	62
50	Whole-Genome Sequencing Accurately Identifies Resistance to Extended-Spectrum β Lactams for Major Gram-Negative Bacterial Pathogens. <i>Clinical Infectious Diseases</i> , 2017 , 65, 738-745	11.3	38
49	Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.6	82
48	Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.6	232
47	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: Clinical Effectiveness and Evolution of Resistance. <i>Clinical Infectious Diseases</i> , 2017 , 65, 110-120	11.3	166
46	Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.6	237
45	Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β Lactamase Protein Engineering. <i>MBio</i> , 2017 , 8,	7.6	66
44	Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. <i>PLoS ONE</i> , 2017 , 12, e0173286	3.6	32
43	Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1615-1618	11.3	284
42	Adverse Events Lead to Drug Discontinuation More Commonly among Patients Who Receive Nafcillin than among Those Who Receive Oxacillin. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3090-5	5.6	14
41	The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. <i>BMC Infectious Diseases</i> , 2016 , 16, 655	3.9	19
40	Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against <i>Klebsiella pneumoniae</i> Carbapenemase- and Extended-Spectrum- β Lactamase-Producing Enterobacter Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5200-14	5.6	34

39	Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3227-31	5.6	70
38	Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies. <i>Journal of Fungi (Basel, Switzerland)</i> , 2016 , 2,	5.4	9
37	Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. <i>PLoS ONE</i> , 2016 , 11, e0153247	3.6	76
36	Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3558-62	5.6	13
35	Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3187-92	5.6	31
34	Rapid Detection of FKS-Associated Echinocandin Resistance in <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 6573-6577	5.6	47
33	Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3585-3587	4.9	10
32	Effects of <i>Klebsiella pneumoniae</i> carbapenemase subtypes, extended-spectrum β -lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant <i>K. pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5793-7	5.6	85
31	Rate of FKS Mutations among Consecutive <i>Candida</i> Isolates Causing Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7465-70	5.6	35
30	Clinical perspectives on echinocandin resistance among <i>Candida</i> species. <i>Current Opinion in Infectious Diseases</i> , 2015 , 28, 514-22	5.2	48
29	Spontaneous fungal peritonitis: a devastating complication of cirrhosis. <i>Mycoses</i> , 2015 , 58, 387-93	5	16
28	Colistin-resistant <i>Acinetobacter baumannii</i> : beyond carbapenem resistance. <i>Clinical Infectious Diseases</i> , 2015 , 60, 1295-303	11.3	234
27	Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing <i>Klebsiella pneumoniae</i> may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1797-801	5.6	24
26	Abdominal candidiasis is a hidden reservoir of echinocandin resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7601-5	5.6	74
25	Epidemiology and clinical outcomes of patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteriuria. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3100-4	5.6	25
24	KPC-producing <i>Klebsiella pneumoniae</i> strains that harbor AAC(6)-Ib exhibit intermediate resistance to amikacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7597-600	5.6	16
23	Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing <i>Klebsiella pneumoniae</i> strains with various ompK36 genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3521-5	5.6	32
22	<i>Candida</i> Biofilm: Clinical Implications of Recent Advances in Research. <i>Current Fungal Infection Reports</i> , 2014 , 8, 72-80	1.3	1

21	Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant <i>Staphylococcus aureus</i> bacteraemia with elevated vancomycin minimum inhibitory concentrations. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 557-63	13.9	28
20	Real-world experience with echinocandin MICs against <i>Candida</i> species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1897-906	5.6	55
19	Carbapenem-resistant <i>Klebsiella pneumoniae</i> strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4443-51	5.6	81
18	In vitro responses of <i>Acinetobacter baumannii</i> to two- and three-drug combinations following exposure to colistin and doripenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1195-9	5.6	32
17	Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant <i>Candida glabrata</i> strains and Echinocandin resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 6361-5	5.6	49
16	Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing <i>Klebsiella pneumoniae</i> strains to doripenem and doripenem-colistin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5258-65	5.6	67
15	Characterization of porin expression in <i>Klebsiella pneumoniae</i> Carbapenemase (KPC)-producing <i>K. pneumoniae</i> identifies isolates most susceptible to the combination of colistin and carbapenems. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2147-53	5.6	42
14	Caspofungin MICs correlate with treatment outcomes among patients with <i>Candida glabrata</i> invasive candidiasis and prior echinocandin exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 3528-35	5.6	83
13	Fluconazole versus an echinocandin for <i>Candida glabrata</i> fungaemia: a retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 922-6	4.9	40
12	<i>Staphylococcus aureus</i> infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 1199-206	1	48
11	Epidemiology, clinical characteristics and outcomes of extensively drug-resistant <i>Acinetobacter baumannii</i> infections among solid organ transplant recipients. <i>PLoS ONE</i> , 2012 , 7, e52349	3.6	98
10	Performance of <i>Candida</i> real-time polymerase chain reaction, β -D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1240-8	11.3	204
9	Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2371-7	5.6	101
8	The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4862-9	5.6	134
7	The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3395-8	5.6	63
6	Invasive aspergillosis among heart transplant recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction syndrome. <i>Scandinavian Journal of Infectious Diseases</i> , 2012 , 44, 982-6		7
5	Comparison of an <i>Aspergillus</i> real-time polymerase chain reaction assay with galactomannan testing of bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. <i>Clinical Infectious Diseases</i> , 2011 , 52, 1218-26	11.3	103
4	Paradoxical effect of caspofungin against <i>Candida</i> bloodstream isolates is mediated by multiple pathways but eliminated in human serum. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2641-7	5.6	60

3	Five-minute exposure to caspofungin results in prolonged postantifungal effects and eliminates the paradoxical growth of <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3598-602	5.6	13
2	Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 1308-11	5.6	54
1	High mortality rates among solid organ transplant recipients infected with extensively drug-resistant <i>Acinetobacter baumannii</i> : using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011 , 70, 246-52	2.8	62